TY  - JOUR
AU  - Katayama, Sonja
AU  - Habl, Gregor
AU  - Kessel, Kerstin
AU  - Edler, Lutz
AU  - Debus, Juergen
AU  - Herfarth, Klaus
AU  - Sterzing, Florian
TI  - Helical intensity-modulated radiotherapy of the pelvic lymph nodes with integrated boost to the prostate bed - initial results of the PLATIN 3 Trial.
JO  - BMC cancer
VL  - 14
IS  - 1
SN  - 1471-2407
CY  - London
PB  - BioMed Central
M1  - DKFZ-2017-02858
SP  - 20
PY  - 2014
AB  - Adjuvant and salvage radiotherapy of the prostate bed are established treatment options for prostate cancer. While the benefit of an additional radiotherapy of the pelvic lymph nodes is still under debate, the PLATIN 3 prospective phase II clinical trial was initiated to substantiate toxicity data on postoperative IMRT of the pelvic lymph nodes and the prostate bed.From 2009 to 2011, 40 patients with high-risk prostate cancer after prostatectomy with pT3 R0/1 M0 or pT2 R1 M0 or a PSA recurrence and either > 20
KW  - Androgen Antagonists (NLM Chemicals)
KW  - Antineoplastic Agents, Hormonal (NLM Chemicals)
KW  - Kallikreins (NLM Chemicals)
KW  - kallikrein-related peptidase 3, human (NLM Chemicals)
KW  - Prostate-Specific Antigen (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:24422782
C2  - pmc:PMC3893457
DO  - DOI:10.1186/1471-2407-14-20
UR  - https://inrepo02.dkfz.de/record/126830
ER  -